A Study to Evaluate the Treatment of Lumbar Spinal Stenosis (LSS) with the MILD Procedure

Overview

Información sobre este estudio

The purpose of this study is to examine functional improvement in lumbar spinal stenosis (LSS) patients with neurogenic claudication who are treated with the MILD procedure plus conventional medical management (CMM) compared to those treated with CMM alone, as the control.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Patients experiencing neurogenic claudication symptoms for at least 3 months duration. 
  • LSS with neurogenic claudication. 
  • Radiologic evidence of LSS with unilateral or bilateral ligamentum flavum ≥ 2.5mm confirmed by pre-op MRI or CT performed within 12 months of baseline visit. 
  • Patients with comorbid conditions commonly associated with spinal stenosis, such as osteophytes, facet hypertrophy, minor spondylolisthesis (Grade I without instability), foraminal stenosis, and/or disk protrusion may be included unless the treating physician has determined that the condition is too advanced. 
  • Stable opioid intake with no change during 30 days prior to enrollment. 
  • Available to complete all follow-up visits.

Exclusion Criteria: 

  • ODI Score < 31 (0-100 ODI Scale). 
  • NPRS Score < 5 (0-10 NPRS Scale). 
  • Lumbar epidural injections during eight weeks prior to study enrollment.
  • Baseline analgesic medication greater than 90 milligram morphine equivalent (MME). 
  • Prior surgery at the same treatment level. 
  • Previously received interspinous spacer at the same treatment level. 
  • Previously received intradiscal procedure at the same treatment level. 
  • Previously received vertebral augmentation procedure at the same treatment level. 
  • Previously received the MILD procedure at the same treatment level.
  • Received radiofrequency ablation at the same or the adjacent levels within 6 months prior to study enrollment. 
  • History of spinal fractures with current related pain symptoms. 
  • Grade II or higher spondylolisthesis. 
  • Motor deficit or disabling back and/or leg pain from causes other than LSS neurogenic claudication (e.g., acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.). 
  • Unable to walk ≥ 10 feet unaided before being limited by pain. In this context, 'unaided' means without the use of a cane, walker, railing, wall, another person or any other means of walking assistance. 
  • Previously randomized and/or treated in this clinical study. 
  • Epidural lipomatosis (if it is deemed to be a significant contributor of canal narrowing by the physician). 
  • On (or pending) Workman's Compensation or known to be considering litigation associated with back pain.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Tim Lamer, M.D.

Cerrado para la inscripción

Contact information:

Matthew Johnson R.R.T., L.R.T.

(507)255-8248

Johnson.Matthew6@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20462494

Mayo Clinic Footer